James W Catto

List of Publications by Year in Descending Order

242 papers	14,249 citations	57 h-index	115 g-index
320 ext. papers	18,184 ext. citations	7.5 avg, IF	6.37 L-index

#	Paper	IF	Citations
242	Optimal Dissemination of Scientific Manuscripts via Social Media: A Prospective Trial Comparing Visual Abstracts Versus Key Figures in Consecutive Original Manuscripts Published in European Urology.. *European Urology*, **2022**,	10.2	5
241	Measuring Patient Compliance With Remote Monitoring Following Discharge From Hospital After Major Surgery (DREAMPath): Protocol for a Prospective Observational Study.. *JMIR Research Protocols*, **2022**, 11, e30638	2	
240	DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801). a randomized phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.. *Journal of Clinical Oncology*, **2022**, 40, TPS284-TPS284	2.2	
239	Real-world evidence from a single U.K. cancer center for atezolizumab in second-line setting in advanced urothelial cancer: Moving beyond clinical trials.. *Journal of Clinical Oncology*, **2022**, 40, 461-461	2.2	
238	A phase 3, randomized, open-label, multicenter, global study of the efficacy and safety of durvalumab (D) + tremelimumab (T) + enfortumab vedotin (EV) or D + EV for neoadjuvant treatment in cisplatin-ineligible muscle-invasive bladder cancer (MIBC) (VOLGA).. *Journal of Clinical*	2.2	0
237	Reply to Benjamin Davies, Keith Kowalczyk RE: Zachary Klaassen, Emily Vertosick, Andrew J. Vickers, et al. Optimal Dissemination of Scientific Manuscripts via Social Media: A Prospective Trial Comparing Visual Abstracts Versus Key Figures in Consecutive Original Manuscripts. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.01.041.. *European Urology*, **2022**, 82, e12-e12	10.2	
236	Case of the month from the University of Sheffield, UK : Expediting definitive treatment in patients with invasive bladder cancer: an MRI -guided pathway. *BJU International*, **2022**, 129, 691-694	5.6	
235	How to Treat a Patient with T1 High-grade Disease and No Tumour on Repeat Transurethral Resection of the Bladder?. *European Urology Oncology*, **2021**, 4, 663-669	6.7	0
234	The Impact of Centralised Services on Metric Reflecting High-quality Performance: Outcomes from 1110 Consecutive Radical Cystectomies at a Single Centre. *European Urology Focus*, **2021**, 7, 554-565	5.1	3
233	Radical Cystectomy in England from 2013 to 2019 on 12,644 patients: An analysis of national trends and comparison of surgical approaches using Hospital Episode Statistics data.. *BJUI Compass*, **2021**, 2, 338-347	0.9	1
232	Quality of Life After Bladder Cancer: A Cross-sectional Survey of Patient-reported Outcomes. *European Urology*, **2021**, 79, 621-632	10.2	13
231	Prehabilitation Exercise Before Urologic Cancer Surgery: A Systematic and Interdisciplinary Review. *European Urology*, **2021**,	10.2	4
230	Urethral recurrence after radical cystoprostatectomy: Experience from a high-volume tertiary referral centre. *Journal of Clinical Urology*, **2021**, 14, 238-245	0.2	
229	Best Practices to Optimise Quality and Outcomes of Transurethral Resection of Bladder Tumours. *European Urology Oncology*, **2021**, 4, 12-19	6.7	11
228	Radical Cystectomy Against Intravesical BCG for High-Risk High-Grade Nonmuscle Invasive Bladder Cancer: Results From the Randomized Controlled BRAVO-Feasibility Study. *Journal of Clinical Oncology*, **2021**, 39, 202-214	2.2	12
227	Impact of Anaesthetist Volume on Radical Cystectomy Outcomes. *European Urology Focus*, **2021**, 7, 117-123	5.1	4
226	Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE). *Clinical Cancer Research*, **2021**, 27, 1882-1892	12.9	6

225	DNA methyltransferase inhibitor guadecitabine combined with cisplatin and gemcitabine chemotherapy (SPIRE): Randomized expansion phase as neoadjuvant therapy for bladder urothelial carcinoma.. *Journal of Clinical Oncology*, **2021**, 39, 447-447	2.2	
224	DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)—A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.. *Journal of Clinical Oncology*, **2021**, 39, TPS266-TPS266	2.2	
223	Comparing an Imaging-guided Pathway with the Standard Pathway for Staging Muscle-invasive Bladder Cancer: Preliminary Data from the BladderPath Study. *European Urology*, **2021**, 80, 12-15	10.2	9
222	Bladder cancer: shedding light on the most promising investigational drugs in clinical trials. *Expert Opinion on Investigational Drugs*, **2021**, 30, 837-855	5.9	4
221	Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021. *European Urology*, **2021**, 80, 703-711	10.2	16
220	The Scottish Bladder Cancer Quality Performance Indicators Influencing Outcomes, Prognosis, and Surveillance (Scot BC Quality OPS) Clinical Project. *European Urology Focus*, **2021**, 7, 905-908	5.1	0
219	Genome-wide Meta-analysis Identifies Novel Genes Associated with Recurrence and Progression in Non-muscle-invasive Bladder Cancer. *European Urology Oncology*, **2021**, 5, 70-70	6.7	0
218	The IDENTIFY study: the investigation and detection of urological neoplasia in patients referred with suspected urinary tract cancer - a multicentre observational study. *BJU International*, **2021**, 128, 440-450	5.6	4
217	Defining Factors Associated with High-quality Surgery Following Radical Cystectomy: Analysis of the British Association of Urological Surgeons Cystectomy Audit. *European Urology Open Science*, **2021**, 33, 1-10	0.9	0
216	Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic. *European Urology*, **2020**, 78, 29-42	10.2	71
215	Molecular Characterization of Upper Tract Urothelial Carcinoma in the Era of Next-generation Sequencing: A Systematic Review of the Current Literature. *European Urology*, **2020**, 78, 209-220	10.2	29
214	Diagnostic Performance of Vesical Imaging Reporting and Data System for the Prediction of Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. *European Urology Oncology*, **2020**, 3, 306-315	6.7	46
213	Comparing open-radical cystectomy and robot-assisted radical cystectomy: current status and analysis of the evidence. *Current Opinion in Urology*, **2020**, 30, 400-406	2.8	2
212	CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer. *BJU International*, **2020**, 125, 817-826	5.6	12
211	Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. *Lancet, The*, **2020**, 395, 1268-1277	40	133
210	IDENTIFY: The investigation and detection of urological neoplasia in patients referred with suspected urinary tract cancer: A multicentre cohort study. *International Journal of Surgery Protocols*, **2020**, 21, 8-12	1.1	2
209	Critical analysis of quality of life and cost-effectiveness of enhanced recovery after surgery (ERAS) for patients undergoing urologic oncology surgery: a systematic review. *World Journal of Urology*, **2020**, 1	4	9
208	Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial **2020**, 8,		14

207	Reporting Radical Cystectomy Outcomes Following Implementation of Enhanced Recovery After Surgery Protocols: A Systematic Review and Individual Patient Data Meta-analysis. *European Urology*, **2020**, 78, 719-730	10.2	18
206	Reply to Charalampos Fragkoulis, Georgios Papadopoulos, and Konstantinos Ntoumas's Letter to the Editor re: Francesco Del Giudice, Giovanni Barchetti, Ettore De Berardinis, et al. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated	10.2	1
205	VI-RADS Scoring Criteria for Alternative Risk-adapted Strategies in the Management of Bladder Cancer During the COVID-19 Pandemic. *European Urology*, **2020**, 78, e18-e20	10.2	13
204	Response to guadecitabine (SGI-110) combined with cisplatin and gemcitabine (GCG) in platinum refractory germ cell tumors (GCTs).. *Journal of Clinical Oncology*, **2020**, 38, e17057-e17057	2.2	3
203	Replacing TURBT with mpMRI for staging MIBC: Pilot data from the BladderPath study.. *Journal of Clinical Oncology*, **2020**, 38, 446-446	2.2	3
202	DASL-HiCAP (ANZUP1801): The impact of darolutamide on standard therapy for localized very high-risk cancer of the prostate—A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very	2.2	2
201	A randomized phase II study of erdafitinib (ERDA) versus intravesical chemotherapy (IC) in patients with high-risk nonmuscle invasive bladder cancer (HR-NMIBC) with FGFR mutations or fusions, who recurred after Bacillus Calmette-Guérin (BCG) therapy.. *Journal of Clinical Oncology*, **2020**, 38, TPS603-TPS603	2.2	6
200	Biomarkers predicting oncological outcomes of high-risk non-muscle-invasive bladder cancer. *Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology*, **2020**, 72, 265-278	4.4	6
199	Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT. *Health Technology Assessment*, **2020**, 24, 1-176	4.4	9
198	Phase I/II open label nonrandomized safety and efficacy study of the viral vectored ChAdOx1-MVA 5T4 immunotherapy in combination with PD-1 checkpoint blockade in intermediate-risk localized or locally advanced prostate cancer and advanced metastatic prostate cancer.. *Journal of Clinical*	2.2	
197	Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in the Detection of Clinically Significant Prostate Cancer in the Prostate Imaging Reporting and Data System Era: A Systematic Review and Meta-analysis. *European Urology*, **2020**, 78, 402-414	10.2	65
196	Complication rate after cystectomy following pelvic radiotherapy: an international, multicenter, retrospective series of 682 cases. *World Journal of Urology*, **2020**, 38, 1959-1968	4	12
195	Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection. *European Urology*, **2020**, 77, 101-109	10.2	70
194	The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression. *BJU International*, **2020**, 125, 506-514	5.6	14
193	Is Social Media Worth the Risk for Health Care Professionals?. *European Urology Focus*, **2020**, 6, 427-429	5.1	2
192	Non-visible haematuria for the Detection of Bladder, Upper Tract, and Kidney Cancer: An Updated Systematic Review and Meta-analysis. *European Urology*, **2020**, 77, 583-598	10.2	16
191	Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received. *European Urology*, **2020**, 77, 320-330	10.2	50
190	The Impact of the COVID-19 Pandemic on Genitourinary Cancer Care: Re-envisioning the Future. *European Urology*, **2020**, 78, 731-742	10.2	23

189	Systematic Review and Meta-Analysis of Vesical Imaging-Reporting and Data System (VI-RADS) Inter-Observer Reliability: An Added Value for Muscle Invasive Bladder Cancer Detection. *Cancers*, **2020**, 12,	6.6	17
188	Occupational bladder cancer: A cross section survey of previous employments, tasks and exposures matched to cancer phenotypes. *PLoS ONE*, **2020**, 15, e0239338	3.7	4
187	Reply to Gianluca Giannarini, Vincenzo Ficarra, and Claudio Valotto's Letter to the Editor re: Stephen B. Williams, Marcus G.K. Cumberbatch, Ashish M. Kamat, et al. Reporting Radical Cystectomy Outcomes Following Implementation of Enhanced Recovery After Surgery Protocols: A Systematic Review and Individual Patient Data Meta-analysis. Eur Urol. In press.	10.2	0
186	Telemedicine and Smart Working: Recommendations of the European Association of Urology. *European Urology*, **2020**, 78, 812-819	10.2	24
185	Survey of the Impact of COVID-19 on Oncologists' Decision Making in Cancer. *JCO Global Oncology*, **2020**, 6, 1248-1257	3.7	22
184	The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer. *British Journal of Cancer*, **2020**, 123, 1063-1070	8.7	4
183	Strategies adopted by men to deal with uncertainty and anxiety when following an active surveillance/monitoring protocol for localised prostate cancer and implications for care: a longitudinal qualitative study embedded within the ProtecT trial. *BMJ Open*, **2020**, 10, e036024	3	1
182	Urothelial Carcinoma in Bladder Diverticula: A Multicenter Analysis of Characteristics and Clinical Outcomes. *European Urology Focus*, **2020**, 6, 1226-1232	5.1	6
181	Quality Indicators for Bladder Cancer Services: A Collaborative Review. *European Urology*, **2020**, 78, 43-59	10.2	13
180	Management of Patients with Normal Cystoscopy but Positive Cytology or Urine Markers. *European Urology Oncology*, **2020**, 3, 548-554	6.7	4
179	Occupational bladder cancer: A cross section survey of previous employments, tasks and exposures matched to cancer phenotypes **2020**, 15, e0239338		
178	Occupational bladder cancer: A cross section survey of previous employments, tasks and exposures matched to cancer phenotypes **2020**, 15, e0239338		
177	Occupational bladder cancer: A cross section survey of previous employments, tasks and exposures matched to cancer phenotypes **2020**, 15, e0239338		
176	Occupational bladder cancer: A cross section survey of previous employments, tasks and exposures matched to cancer phenotypes **2020**, 15, e0239338		
175	Quality of life in men living with advanced and localised prostate cancer in the UK: a population-based study. *Lancet Oncology, The*, **2019**, 20, 436-447	21.7	59
174	Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019. *European Urology*, **2019**, 76, 368-380	10.2	26
173	Regional Variations in Quality of Survival Among Men with Prostate Cancer Across the United Kingdom. *European Urology*, **2019**, 76, 228-237	10.2	5
172	Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019. *European Urology*, **2019**, 76, 142-150	10.2	51

171	Multiparametric MRI of the bladder: inter-observer agreement and accuracy with the Vesical Imaging-Reporting and Data System (VI-RADS) at a single reference center. *European Radiology*, **2019**, 29, 5498-5506	8	64
170	Specificity of the Metallothionein-1 Response by Cadmium-Exposed Normal Human Urothelial Cells. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	12
169	Robot-assisted versus open cystectomy in the RAZOR trial. *Lancet, The*, **2019**, 393, 644-645	40	2
168	Factors associated with trial recruitment, preferences, and treatments received were elucidated in a comprehensive cohort study. *Journal of Clinical Epidemiology*, **2019**, 113, 200-213	5.7	2
167	Re: Enzalutamide with Standard First-line Therapy in Metastatic Prostate Cancer. *European Urology*, **2019**, 76, 872-873	10.2	1
166	EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study). *European Urology*, **2019**, 76, 790-813	10.2	76
165	Bladder-sparing treatment in MIBC: where do we stand?. *Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology*, **2019**, 71, 101-112	4.4	13
164	Life and bladder cancer: protocol for a longitudinal and cross-sectional patient-reported outcomes study of Yorkshire (UK) patients. *BMJ Open*, **2019**, 9, e030850	3	3
163	Impact of Centralizing Care for Genitourinary Malignancies to High-volume Providers: A Systematic Review. *European Urology Oncology*, **2019**, 2, 265-273	6.7	44
162	Reply to Jeremy Y.C. Teoh, Thomas R.W. Herrmann, and Marek Babjuk's Letter to the Editor re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting and Data System). Eur Urol 2018;74:294-306. *European Urology*, **2019**, 75, e29-e30	10.2	1
161	A three-gene methylation marker panel for the nodal metastatic risk assessment of muscle-invasive bladder cancer. *Journal of Cancer Research and Clinical Oncology*, **2019**, 145, 811-820	4.9	5
160	Does the robot have a role in radical cystectomy?. *BJU International*, **2019**, 123, 380-382	5.6	2
159	Long-term Outcomes from Re-resection for High-risk Non-muscle-invasive Bladder Cancer: A Potential to Rationalize Use. *European Urology Focus*, **2019**, 5, 650-657	5.1	23
158	Islam and the Urinary Stoma: A Contemporary Theological and Urological Dilemma. *European Urology Focus*, **2019**, 5, 301-305	5.1	6
157	Repeat Transurethral Resection in Non-muscle-invasive Bladder Cancer: A Systematic Review. *European Urology*, **2018**, 73, 925-933	10.2	114
156	Urinary, bowel and sexual health in older men from Northern Ireland. *BJU International*, **2018**, 122, 845-857	5.6	10
155	A miRNA-145/TGF-β1 negative feedback loop regulates the cancer-associated fibroblast phenotype. *Carcinogenesis*, **2018**, 39, 798-807	4.6	30
154	An observational study showed that explaining randomization using gambling-related metaphors and computer-agency descriptions impeded randomized clinical trial recruitment. *Journal of Clinical Epidemiology*, **2018**, 99, 75-83	5.7	18

153	A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial. *Journal of Clinical Epidemiology*, **2018**, 96, 35-46	5.7	9
152	Correction to: Meeting abstracts from the 4th International Clinical Trials Methodology Conference (ICTMC) and the 38th Annual Meeting of the Society for Clinical Trials. *Trials*, **2018**, 19,	2.8	78
151	SPIRE - combining SGI-110 with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer: study protocol for a phase Ib/randomised IIa open label clinical trial. *Trials* , **2018**, 19, 216	2.8	6
150	Occupation and Bladder Cancer Phenotype: Identification of Workplace Patterns That Increase the Risk of Advanced Disease Beyond Overall Incidence. *European Urology Focus*, **2018**, 4, 725-730	5.1	12
149	Predicting Response to Intravesical Bacillus Calmette-Guﾨin Immunotherapy: Are We There Yet? A Systematic Review. *European Urology*, **2018**, 73, 738-748	10.2	77
148	Treatment Strategy for Newly Diagnosed T1 High-grade Bladder Urothelial Carcinoma: New Insights and Updated Recommendations. *European Urology*, **2018**, 74, 597-608	10.2	33
147	Reply to Andrea Necchi, Antonella Messina, and Alberto Briganti's Letter to the Editor re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting and Data System). Eur Urol 2018;74:294-306. *European Urology*, **2018**, 74, e109	10.2	5
146	Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). *European Urology*, **2018**, 74, 294-306	10.2	176
145	Evaluating patient-reported outcome measures (PROMs) for bladder cancer: a systematic review using the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) checklist. *BJU International*, **2018**, 122, 760-773	5.6	21
144	Reply to Mark C. Kendall's Letter to the Editor re: Karl H. Pang, Ruth Groves, Suresh Venugopal, Aidan P. Noon, James W.F. Catto. Prospective Implementation of Enhanced Recovery After Surgery Protocols to Radical Cystectomy. Eur Urol 2018;73:363-71. *European Urology*, **2018**, 74, e66	10.2	3
143	Active Surveillance for Low-risk Prostate Cancer: The European Association of Urology Position in 2018. *European Urology*, **2018**, 74, 357-368	10.2	72
142	Overcoming difficulties with equipoise to enable recruitment to a randomised controlled trial of partial ablation vs radical prostatectomy for unilateral localised prostate cancer. *BJU International*, **2018**, 122, 970-977	5.6	10
141	Partial ablation versus radical prostatectomy in intermediate-risk prostate cancer: the PART feasibility RCT. *Health Technology Assessment*, **2018**, 22, 1-96	4.4	18
140	Re: Comprehensive Molecular Characterization of Muscle Invasive Bladder Cancer. *European Urology*, **2018**, 73, 479-480	10.2	1
139	A New Fuzzy Modeling Framework for Integrated Risk Prognosis and Therapy of Bladder Cancer Patients. *IEEE Transactions on Fuzzy Systems*, **2018**, 26, 1565-1577	8.3	13
138	Prospective Implementation of Enhanced Recovery After Surgery Protocols to Radical Cystectomy. *European Urology*, **2018**, 73, 363-371	10.2	90
137	Robot-assisted radical cystectomy with intracorporeal urinary diversion versus open radical cystectomy (iROC): protocol for a randomised controlled trial with internal feasibility study. *BMJ Open*, **2018**, 8, e020500	3	54
136	Staging the Host: Personalizing Risk Assessment for Radical Cystectomy Patients. *European Urology Oncology*, **2018**, 1, 292-304	6.7	32

135	Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018. *European Urology*, **2018**, 74, 784-795	10.2	265
134	Online Professionalism-2018 Update of European Association of Urology (@Uroweb) Recommendations on the Appropriate Use of Social Media. *European Urology*, **2018**, 74, 644-650	10.2	38
133	Health-related quality of life after treatment for bladder cancer in England. *British Journal of Cancer*, **2018**, 118, 1518-1528	8.7	28
132	Intense Exercise for Survival among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL-GAP4): a multicentre, randomised, controlled phase III study protocol. *BMJ Open*, **2018**, 8, e022899	3	55
131	Multidomain Quantitative Recovery Following Radical Cystectomy for Patients Within the Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion Versus Open Radical Cystectomy Randomised Controlled Trial: The First 30 Patients. *European Urology*, **2018**, 74, 531-534	10.2	21
130	Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of low-risk upper tract urothelial carcinoma. *World Journal of Urology*, **2017**, 35, 355-365	4	27
129	The contemporary landscape of occupational bladder cancer within the United Kingdom: a meta-analysis of risks over the last 80 years. *BJU International*, **2017**, 119, 100-109	5.6	12
128	E-cigarettes and Urologic Health: A Collaborative Review of Toxicology, Epidemiology, and Potential Risks. *European Urology*, **2017**, 71, 915-923	10.2	10
127	Quantification of Urology Related Twitter Traffic Activity through a Standardized List of Social Media Communication Descriptors. *Urology Practice*, **2017**, 4, 349-354	0.8	1
126	An evaluation of morphological and functional multi-parametric MRI sequences in classifying non-muscle and muscle invasive bladder cancer. *European Radiology*, **2017**, 27, 3759-3766	8	50
125	Precision surgery and genitourinary cancers. *European Journal of Surgical Oncology*, **2017**, 43, 893-908	3.6	53
124	Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. *Cell*, **2017**, 171, 540-556.e25	36.2	961
123	Evaluation of a short RNA within Prostate Cancer Gene 3 in the predictive role for future cancer using non-malignant prostate biopsies. *PLoS ONE*, **2017**, 12, e0175070	3.7	1
122	The patientsÞexperience of a bladder cancer diagnosis: a systematic review of the qualitative evidence. *Journal of Cancer Survivorship*, **2017**, 11, 453-461	5.1	37
121	Reply to Lars Egevad, Hemamali Samaratunga, John R. Srigley, Brett Delahunt's Letter to the Editor re: Anthony Zietman, Joseph Smith, Eric Klein, Michael Droller, Prokar Dasgupta, James Catto. Describing the Grade of Prostate Cancer: Consistent Use of Contemporary Terminology Is Now Required. Eur Urol 2016;70:1. *European Urology*, **2017**, 71, e54	10.2	
120	Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial. *European Urology*, **2017**, 71, 381-388	10.2	25
119	Radical cystectomy (bladder removal) against intravesical BCG immunotherapy for high-risk non-muscle invasive bladder cancer (BRAVO): a protocol for a randomised controlled feasibility study. *BMJ Open*, **2017**, 7, e017913	3	17
118	Robotic intracorporeal urinary diversion: practical review of current surgical techniques. *Minerva Urology and Nephrology*, **2017**, 69, 14-25	2.3	5

117	The Role of Tobacco Smoke in Bladder and Kidney Carcinogenesis: A Comparison of Exposures and Meta-analysis of Incidence and Mortality Risks. *European Urology*, **2016**, 70, 458-66	10.2	175
116	Current Histopathologic and Molecular Characterisations of Prostate Cancer: Towards Individualised Prognosis and Therapies. *European Urology*, **2016**, 69, 186-90	10.2	13
115	Consensus guidelines for reporting prostate cancer Gleason Grade. *BJU International*, **2016**, 118, E1-2	5.6	2
114	10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. *New England Journal of Medicine*, **2016**, 375, 1415-1424	59.2	1451
113	Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. *New England Journal of Medicine*, **2016**, 375, 1425-1437	59.2	655
112	Critical Review of Outcomes from Radical Cystectomy: Can Complications from Radical Cystectomy Be Reduced by Surgical Volume and Robotic Surgery?. *European Urology Focus*, **2016**, 2, 19-29	5.1	47
111	Improving Staging in Bladder Cancer: The Increasing Role of Multiparametric Magnetic Resonance Imaging. *European Urology Focus*, **2016**, 2, 113-121	5.1	42
110	Editorial Statement on Gleason Scoring for Prostate Cancer. *International Journal of Radiation Oncology Biology Physics*, **2016**, 95, 1092	4	2
109	Enhanced Recovery after Urological Surgery: A Contemporary Systematic Review of Outcomes, Key Elements, and Research Needs. *European Urology*, **2016**, 70, 176-187	10.2	167
108	Urology Tag Ontology Project: Standardizing Social Media Communication Descriptors. *European Urology*, **2016**, 69, 183-5	10.2	31
107	Exercise for Men with Prostate Cancer: A Systematic Review and Meta-analysis. *European Urology*, **2016**, 69, 693-703	10.2	153
106	Altered RECQL5 expression in urothelial bladder carcinoma increases cellular proliferation and makes RECQL5 helicase activity a novel target for chemotherapy. *Oncotarget*, **2016**, 7, 76140-76150	3.3	12
105	In Reply to Samaratunga et´al. *International Journal of Radiation Oncology Biology Physics*, **2016**, 96, 1127-1128		
104	Enhanced Recovery After Robot-assisted Radical Cystectomy: EAU Robotic Urology Section Scientific Working Group Consensus View. *European Urology*, **2016**, 70, 649-660	10.2	90
103	Reply to Wentao Liu, Xiaokun Zhao, Zhaohui Zhong's Letter to the Editor re: Marcus G. Cumberbatch, Matteo Rota, James W.F. Catto, Carlo La Vecchia. The Role of Tobacco Smoke in Bladder and Kidney Carcinogenesis: A Comparison of Exposures and Meta-analysis of Incidence and Mortality Risks. Eur Urol 2016;70:458-66. *European Urology*, **2016**, 70, e106-e107	10.2	1
102	New Gleason grading system: Statement from the Editors of six journals. *Urologic Oncology: Seminars and Original Investigations*, **2016**, 34, 253	2.8	8
101	The Use of Biomarkers to Manage Men with Metastatic Prostate Cancer: One Day, But Not Yet. *European Urology Focus*, **2016**, 2, 467-468	5.1	
100	Re: Samaratunga et al: Consensus Guidelines for Reporting Prostate Cancer Gleason Grade. *Urology* , **2016**, 96, 179	1.6	

99	Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature. *European Urology*, **2015**, 68, 238-53	10.2	168
98	Genomic Predictors of Outcome in Prostate Cancer. *European Urology*, **2015**, 68, 1033-44	10.2	136
97	Identification and diagnostic performance of a small RNA within the PCA3 and BMCC1 gene locus that potentially targets mRNA. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 268-75	4	5
96	Luzp4 defines a new mRNA export pathway in cancer cells. *Nucleic Acids Research*, **2015**, 43, 2353-66	20.1	39
95	Contemporary Occupational Carcinogen Exposure and Bladder Cancer: A Systematic Review and Meta-analysis. *JAMA Oncology*, **2015**, 1, 1282-90	13.4	135
94	A Comparative Analysis of the Influence of Gender, Pathway Delays, and Risk Factor Exposures on the Long-term Outcomes of Bladder Cancer. *European Urology Focus*, **2015**, 1, 82-89	5.1	8
93	Intratumour heterogeneity in urologic cancers: from molecular evidence to clinical implications. *European Urology*, **2015**, 67, 729-37	10.2	86
92	Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project *Annals of Oncology*, **2015**, 26, 2392-8	10.3	22
91	Exercise interventions for men with prostate cancer. *The Cochrane Library*, **2015**,	5.2	2
90	Robot-assisted radical cystectomy and urinary diversion: technical recommendations from the Pasadena Consensus Panel. *European Urology*, **2015**, 67, 423-31	10.2	47
89	Defining a standard set of patient-centered outcomes for men with localized prostate cancer. *European Urology*, **2015**, 67, 460-7	10.2	136
88	Systematic review and cumulative analysis of perioperative outcomes and complications after robot-assisted radical cystectomy. *European Urology*, **2015**, 67, 376-401	10.2	260
87	Diagnosis and management of urothelial carcinoma in situ of the lower urinary tract: a systematic review. *European Urology*, **2015**, 67, 876-88	10.2	50
86	Best practices in robot-assisted radical cystectomy and urinary reconstruction: recommendations of the Pasadena Consensus Panel. *European Urology*, **2015**, 67, 363-75	10.2	128
85	Systematic review and cumulative analysis of oncologic and functional outcomes after robot-assisted radical cystectomy. *European Urology*, **2015**, 67, 402-22	10.2	158
84	Epidemiology and Risk Factors for Upper Urinary Urothelial Cancers **2015**, 1-30		3
83	High Dimensionality and Scaling-up Performance of RBF Models with Application to Healthcare Informatics. *International Journal of Machine Learning and Computing*, **2015**, 5, 62-67	1.8	
82	Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11. *Clinical Cancer Research*, **2014**, 20, 1990-2000	12.9	132

81	MicroRNA and urothelial cell carcinoma. *BJU International*, **2014**, 113, 811-2	5.6	2
80	Molecular subtyping of bladder cancer using Kohonen self-organizing maps. *Cancer Medicine*, **2014**, 3, 1225-34	4.8	14
79	Identification of differentially expressed long noncoding RNAs in bladder cancer. *Clinical Cancer Research*, **2014**, 20, 5311-21	12.9	50
78	Next-generation RNA sequencing of archival formalin-fixed paraffin-embedded urothelial bladder cancer. *European Urology*, **2014**, 66, 982-6	10.2	27
77	In Memory of John Fitzpatrick. *European Urology*, **2014**, 66, 604	10.2	
76	Molecular markers for urothelial bladder cancer prognosis: toward implementation in clinical practice. *Urologic Oncology: Seminars and Original Investigations*, **2014**, 32, 1078-87	2.8	37
75	European Association of Urology (@Uroweb) recommendations on the appropriate use of social media. *European Urology*, **2014**, 66, 628-32	10.2	54
74	MicroRNA-99a and 100 mediated upregulation of FOXA1 in bladder cancer. *Oncotarget*, **2014**, 5, 6375-86	3.3	22
73	Noncoding RNA in bladder cancer: a specific focus upon high-risk nonmuscle invasive disease. *Current Opinion in Urology*, **2014**, 24, 506-11	2.8	11
72	BPH and prostate cancer risk. *Indian Journal of Urology*, **2014**, 30, 214-8	0.8	35
71	Early detection of prostate cancer: European Association of Urology recommendation. *European Urology*, **2013**, 64, 347-54	10.2	106
70	Systematic review of complications of prostate biopsy. *European Urology*, **2013**, 64, 876-92	10.2	564
69	The mutational landscape of prostate cancer. *European Urology*, **2013**, 64, 567-76	10.2	144
68	Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature. *European Urology*, **2013**, 64, 624-38	10.2	156
67	Comparative outcomes of primary, recurrent, and progressive high-risk non-muscle-invasive bladder cancer. *European Urology*, **2013**, 63, 145-54	10.2	56
66	Epidemiology and risk factors of urothelial bladder cancer. *European Urology*, **2013**, 63, 234-41	10.2	1180
65	Distinct patterns and behaviour of urothelial carcinoma with respect to anatomical location: how molecular biomarkers can augment clinico-pathological predictors in upper urinary tract tumours. *World Journal of Urology*, **2013**, 31, 21-9	4	51
64	Disease specific mortality in patients with low risk bladder cancer and the impact of cystoscopic surveillance. *Journal of Urology*, **2013**, 189, 828-33	2.5	34

63	Bladder cancer in 2012: Challenging current paradigms. *Nature Reviews Urology*, **2013**, 10, 67-8	5.5	15
62	Screening for bladder cancer: rationale, limitations, whom to target, and perspectives. *European Urology*, **2013**, 63, 1049-58	10.2	47
61	Snapshot of transurethral resection of bladder tumours in the United Kingdom Audit (STUKA). *BJU International*, **2013**, 112, 930-5	5.6	10
60	EORTC risk tables - their usefulness in the assessment of recurrence and progression risk in non-muscle-invasive bladder cancer in Polish patients. *Urologia Polska*, **2013**, 66, 14-20		15
59	Treatment options available for bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer. *European Urology*, **2012**, 62, 1088-96	10.2	57
58	Molecular mechanisms of cisplatin resistance in bladder cancer. *Expert Review of Anticancer Therapy* , **2012**, 12, 271-81	3.5	68
57	Integrated epigenome profiling of repressive histone modifications, DNA methylation and gene expression in normal and malignant urothelial cells. *PLoS ONE*, **2012**, 7, e32750	3.7	28
56	The long-term outcome of treated high-risk nonmuscle-invasive bladder cancer: time to change treatment paradigm?. *Cancer*, **2012**, 118, 5525-34	6.4	31
55	Occupational exposure to crack detection dye penetrants and the potential for bladder cancer. *Occupational and Environmental Medicine*, **2012**, 69, 300-1	2.1	10
54	Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study. *BMJ, The*, **2012**, 344, d7894	5.9	163
53	KISS1 methylation and expression as tumor stratification biomarkers and clinical outcome prognosticators for bladder cancer patients. *American Journal of Pathology*, **2011**, 179, 540-6	5.8	39
52	Regulation of neutrophil senescence by microRNAs. *PLoS ONE*, **2011**, 6, e15810	3.7	50
51	MicroRNA in prostate, bladder, and kidney cancer: a systematic review. *European Urology*, **2011**, 59, 671-81	10.2	355
50	Epigenetics in prostate cancer: biologic and clinical relevance. *European Urology*, **2011**, 60, 753-66	10.2	164
49	Words of wisdom. Re: Comorbidity and mortality results from a randomised prostate cancer screening trial. *European Urology*, **2011**, 60, 867	10.2	
48	Hypermethylation of CpG islands and shores around specific microRNAs and mirtrons is associated with the phenotype and presence of bladder cancer. *Clinical Cancer Research*, **2011**, 17, 1287-96	12.9	82
47	Global epigenetic profiling in bladder cancer. *Epigenomics*, **2011**, 3, 35-45	4.4	36
46	Epigenetic regulation of microRNA expression in cancer. *Methods in Molecular Biology*, **2011**, 676, 165-84	1.4	17

45	Time to change our approach to high-risk nonmuscle-invasive bladder cancer management in the United Kingdom? Observations from the British Association of Urological Surgeons Cancer Registry. *BJU International*, **2010**, 106, 593-4	5.6	0
44	Markers for detection of prostate cancer. *Cancers*, **2010**, 2, 1125-54	6.6	30
43	Targeting chemotherapy to advanced bladder cancer patients most likely to benefit. *Future Oncology*, **2010**, 6, 193-6	3.6	1
42	Low frequency of epigenetic events in urothelial tumors in young patients. *Journal of Urology*, **2010**, 184, 459-63	2.5	20
41	Haematuria. *Surgery*, **2010**, 28, 589-593	0.3	1
40	The application of artificial intelligence to microarray data: identification of a novel gene signature to identify bladder cancer progression. *European Urology*, **2010**, 57, 398-406	10.2	34
39	Neurofuzzy modeling to determine recurrence risk following radical cystectomy for nonmetastatic urothelial carcinoma of the bladder. *Clinical Cancer Research*, **2009**, 15, 3150-5	12.9	19
38	Distinct microRNA alterations characterize high- and low-grade bladder cancer. *Cancer Research*, **2009**, 69, 8472-81	10.1	260
37	FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. *European Urology*, **2009**, 55, 650-7	10.2	90
36	Words of wisdom. Re: Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. *European Urology*, **2009**, 55, 1487-8	10.2	
35	Prostate cancer proteomics: The urgent need for clinically validated biomarkers. *Proteomics - Clinical Applications*, **2009**, 3, 197-212	3.1	7
34	A comparison of the performance of microsatellite and methylation urine analysis for predicting the recurrence of urothelial cell carcinoma, and definition of a set of markers by Bayesian network analysis. *BJU International*, **2008**, 101, 1448-53	5.6	44
33	Contribution of a single repeat PSA test to prostate cancer risk assessment: experience from the ProtecT study. *European Urology*, **2008**, 53, 777-84	10.2	16
32	Haematuria. *Surgery*, **2008**, 26, 150-153	0.3	1
31	Urological diagnosis history and investigations. *Surgery*, **2008**, 26, 154-160	0.3	
30	iTRAQ-facilitated proteomic analysis of human prostate cancer cells identifies proteins associated with progression. *Journal of Proteome Research*, **2008**, 7, 897-907	5.6	95
29	Old and New Urinary Markers: Which One is the PSA for Bladder Cancer?. *European Urology Supplements*, **2008**, 7, 422-425	0.9	3
28	Promoter hypermethylation in circulating blood cells identifies prostate cancer progression. *International Journal of Cancer*, **2008**, 122, 952-6	7.5	66

27	Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center: in regard to Kotwal et al. (Int J Radiat Oncol Biol Phys 2008;70:456-463). *International Journal of Radiation Oncology Biology Physics* , **2008**, 71, 1601-2; author reply 1602	4	1
26	Behavior of urothelial carcinoma with respect to anatomical location. *Journal of Urology*, **2007**, 177, 1715-20	2.5	131
25	Application of artificial intelligence to the management of urological cancer. *Journal of Urology*, **2007**, 178, 1150-6	2.5	69
24	DNA methylation and immunohistochemical analysis of the S100A4 calcium binding protein in human prostate cancer. *Prostate*, **2007**, 67, 341-7	4.2	15
23	Human prostate cancer cells express neuroendocrine cell markers PGP 9.5 and chromogranin A. *Prostate*, **2007**, 67, 1761-9	4.2	46
22	Clinically localised prostate cancer is microsatellite stable. *BJU International*, **2007**, 99, 1031-5	5.6	12
21	Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage. *Clinical Cancer Research*, **2007**, 13, 1720-5	12.9	126
20	Promoter hypermethylation identifies progression risk in bladder cancer. *Clinical Cancer Research*, **2007**, 13, 2046-53	12.9	150
19	The changing face of prostate cancer: can gains in epigenetic knowledge translate into improvements in clinical care?. *Journal of Molecular Medicine*, **2006**, 84, 883-5	5.5	2
18	Neuro-fuzzy modeling: an accurate and interpretable method for predicting bladder cancer progression. *Journal of Urology*, **2006**, 175, 474-9	2.5	27
17	Multifocal urothelial cancers with the mutator phenotype are of monoclonal origin and require panurothelial treatment for tumor clearance. *Journal of Urology*, **2006**, 175, 2323-30	2.5	51
16	Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma. *Journal of Pathology*, **2006**, 209, 336-43	9.4	66
15	The Use of Proteomics in Urological Research. *EAU Update Series*, **2005**, 3, 171-179		5
14	The Role of Genetic Instability in the Pathogenesis and Progression of Urothelial Carcinoma. *EAU Update Series*, **2005**, 3, 180-188		
13	Assessing the patient with a urological problem. *Foundation Years*, **2005**, 1, 1-7		
12	The Road to Cystectomy: Who, When and Why?. *EAU Update Series*, **2005**, 3, 118-128		4
11	Simultaneous augmentation cystoplasty is associated with earlier rather than increased artificial urinary sphincter infection. *Journal of Urology*, **2005**, 173, 1237-41	2.5	14
10	Promoter hyper-methylation of calcium binding proteins S100A6 and S100A2 in human prostate cancer. *Prostate*, **2005**, 65, 322-30	4.2	43

9	Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. *Journal of Clinical Oncology*, **2005**, 23, 2903-10	2.2	249
8	Dysregulated expression of S100A11 (calgizzarin) in prostate cancer and precursor lesions. *Human Pathology*, **2004**, 35, 1385-91	3.7	59
7	Less is more: artificial intelligence and gene-expression arrays. *Lancet, The*, **2004**, 364, 2003-4	40	6
6	Differential expression of hMLH1 and hMSH2 is related to bladder cancer grade, stage and prognosis but not microsatellite instability. *International Journal of Cancer*, **2003**, 105, 484-90	7.5	64
5	Distinct patterns of microsatellite instability are seen in tumours of the urinary tract. *Oncogene*, **2003**, 22, 8699-706	9.2	113
4	Artificial intelligence in predicting bladder cancer outcome: a comparison of neuro-fuzzy modeling and artificial neural networks. *Clinical Cancer Research*, **2003**, 9, 4172-7	12.9	59
3	Pancreatic debridement in a district general hospital--viable or vulnerable?. *Annals of the Royal College of Surgeons of England*, **2002**, 84, 309-13	1.4	7
2	Theepigenetic profile of bladder cancer323-337		
1	Safety and exceptional immunogenicity of novel 5T4 viral vectored vaccination regimes in early stage prostate cancer: a phase I clinical trial		1